Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years

Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with moderate-to-severe atopic dermatitis. What Happened: The company’s data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV). The EADV is a leading professional society focused on the fields of dermatology and venereology. Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years ...